Comparison · NCT02429427-sae
Celecoxib vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Celecoxib vs Placebo: serious adverse events. Trial comparisons, record NCT02429427-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02429427-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0843 | 0.0722 | 0.0983 | wilson | |
| Risk in group 2 | 0.0737 | 0.0582 | 0.0931 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0106 | -0.0122 | 0.0315 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.14 | 0.863 | 1.52 | log | |
| Odds ratio, group 1 over group 2 | 1.16 | 0.853 | 1.57 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Celecoxib than on Placebo | 94.4 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Celecoxib | Patients in this arm will receive 400mg of celecoxib once daily. In addition, Hormone Receptor (+) patients will receive endocrine treatment according to local practice.~Celecoxib: Patients will receive 400mg of Celecoxib once daily for two years or until disease progression (if before the two years limit) or until development of unacceptable toxicities. In addition ER(+) patients will receive endocrine treatment according to local practice. | 148 | 1,755 | EG000 |
| Group 2 | Placebo | Patients in this arm will receive 2 tablets once daily. In addition Hormone Receptor (+) patients will receive endocrine treatment according to local practice.~Placebo: Two capsules once daily with food | 64 | 868 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- From the time of randomisation until 30 days after the discontinuation of celecoxib/placebo (i.e. 2 years or sooner if patient discontinued early).
Source ClinicalTrials.gov
Trial
- Title
- European Celecoxib Trial in Primary Breast Cancer
- NCT number
- NCT02429427
- Phases
- PHASE3
- Conditions
- Breast Cancer
- Interventions
- Celecoxib, Placebo
- Lead sponsor
- Imperial College London
- Results first posted
- 2020-06-23
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02429427?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02429427-sae